Skip to main content

Table 2 Figures and assumptions used for the calculations.

From: Implementing guidelines in primary care: can population impact measures help?

   MI MI + CHF
Proportion of practice population of 10,000 .056 [9] .006 [10, 11]
Proportion eligible for treatment    
  ACE-I .75 .75
  BB .75 .75
  Aspirin .90 N/a
  Statins .80 N/a
  Spironolactone N/a .75
Proportion eligible for incremental treatment –
(proportion currently on treatment)
   
  ACE-I .27 (.48) .16 (.59)
  BB .43 (.32) .43 (.32)
  Aspirin .19 (.71) N/a
  Statins .61 (.19) N/a
  Spironolactone N/a .55 (.20)
Baseline risk of death in the next year expressed
as a proportion
.09 [10] .29 [10]
RRR from trials.    
  ACE-I .16 [15] .15 [3]
  BB .23 [16] .21 [17]
  Aspirin .12 [4] N/a
  Statins .21 [18] N/a
  Spironolactone N/a .30 [19]
Costs (from MIMS, 2001)    
  ACE-I (Ramipril 2.5 mg @ €7.51/28; Lisinopril 10 mg @9.70/28) €100 per year €100 per year
  BB (Atenolol 25 mg @ €4.40/28; Metoprolol 100 mg @€6.68/56) €45 per year €45 per year
  Spironolactone 100 mg @ €39.50/100   €144 per year
  Aspirin @ 94p/28 €11 per year  
  Statins (Simvastatin 20 mg or Pravastatin 20 mg@ €29.69/28) €386 per year